Home Other Building Blocks Vilazodone hydrochloride

Vilazodone hydrochloride

CAS No.:
163521-08-2
Catalog Number:
AG001U74
Molecular Formula:
C26H28ClN5O2
Molecular Weight:
477.9858
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
250mg
98%
In Stock USA
United States
$63
- +
1g
98%
In Stock USA
United States
$132
- +
5g
98%
In Stock USA
United States
$444
- +
10g
98%
In Stock USA
United States
$669
- +
25g
98%
In Stock USA
United States
$1388
- +
Product Description
Catalog Number:
AG001U74
Chemical Name:
Vilazodone hydrochloride
CAS Number:
163521-08-2
Molecular Formula:
C26H28ClN5O2
Molecular Weight:
477.9858
MDL Number:
MFCD00940014
IUPAC Name:
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride
InChI:
InChI=1S/C26H27N5O2.ClH/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32;/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32);1H
InChI Key:
RPZBRGFNBNQSOP-UHFFFAOYSA-N
SMILES:
N#Cc1ccc2c(c1)c(CCCCN1CCN(CC1)c1ccc3c(c1)cc(o3)C(=O)N)c[nH]2.Cl
UNII:
U8HTX2GK8J
Properties
Complexity:
729  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
477.193g/mol
Formal Charge:
0
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0
Molecular Weight:
477.993g/mol
Monoisotopic Mass:
477.193g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
102A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
A review of current evidence for vilazodone in major depressive disorder. International journal of psychiatry in clinical practice 20130801
Evidence for the use of vilazodone in the treatment of major depressive disorder. Expert opinion on pharmacotherapy 20121001
Vilazodone for the treatment of major depressive disorder. Pharmacotherapy 20121001
Vilazodone's comparative merits yet to be demonstrated. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120915
Vilazodone: a novel antidepressant. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120915
Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International journal of clinical practice 20120401
New drugs 2012 part I. Nursing 20120301
The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Current medical research and opinion 20120101
Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Current medicinal chemistry 20120101
A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. Journal of clinical psychopharmacology 20111001
Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. The Journal of clinical psychiatry 20110901
A new antidepressant. Behavioral healthcare 20110901
Vilazodone (Viibryd)--a new antidepressant. The Medical letter on drugs and therapeutics 20110711
Vilazodone for the treatment of depression. The Annals of pharmacotherapy 20110701
Vilazodone: in major depressive disorder. CNS drugs 20110701
Vilazodone: a new treatment option for major depressive disorder. Drugs of today (Barcelona, Spain : 1998) 20110701
A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. The Journal of clinical psychiatry 20110401
Vilazodone: another novel atypical antidepressant drug. Journal of psychosocial nursing and mental health services 20110301
Vilazodone approved for major depression. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110301
Vilazodone hydrochloride, linagliptin, and alcaftadine. Journal of the American Pharmacists Association : JAPhA 20110101
Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert opinion on investigational drugs 20091101
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry 20090301
Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS neuroscience & therapeutics 20090101
Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs : the investigational drugs journal 20070301
Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus. European journal of pharmacology 20050704
Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. European journal of pharmacology 20050307
Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. European journal of pharmacology 20041103
Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity. Bioorganic & medicinal chemistry 20040915
A new synthesis of indole 5-carboxylic acids and 6-hydroxy-indole-5-carboxylic acids in the preparation of an o-hydroxylated metabolite of vilazodone. Bioorganic & medicinal chemistry letters 20040517
Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica; the fate of foreign compounds in biological systems 20040301
Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. The Journal of pharmacology and experimental therapeutics 20020901
Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacology 20010501
Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test. European journal of pharmacology 20010302
Properties